Join us for a high-impact Strategic Investor Spotlight with Eli Lilly, a global medicine company with nearly 150 years of experience turning science into healing to improve lives around the world. Lilly is recognized for its leadership in biotechnology, chemistry, and genetic medicine, and for advancing breakthrough therapies across diabetes, obesity, Alzheimer’s disease, immunology, and oncology – along with a strong commitment to collaboration with innovators and entrepreneurs.
Kristina Kitko, the director of venture science at Eli Lilly for the West Coast USA, will talk about Eli Lilly’s larger Corporate Business Development efforts, primarily targeting early-stage innovation across Lilly’s five core therapeutic areas. Kristina’s role supports Lilly’s multiple external venture investments in both funds (over $2 billion) and companies globally, as well as due diligence and search and evaluation initiatives.
Next hear from Vanessa Braunstein, Sr. Director, TuneLab AI Drug Discovery of Eli Lilly, as she shares how Lilly works with entrepreneurs and engages with early-stage innovators. Vanessa will discuss how biotech companies can access AI-enabled drug discovery through Lilly TuneLab.
This exclusive event includes an educational program and a networking session with refreshments, offering Washington state startups and researchers a unique opportunity to learn more about how to engage with Eli Lilly.
Agenda:
- 11:45 AM – Doors open for registration
- 12:00 PM – Introduction
- 12:10 PM – Eli Lilly Presentation
- 12:45 PM – Q&A
- 1:30 PM – Networking